A one-year cost–utility analysis of REBOA versus RTACC for non-compressible torso haemorrhage

File Description SizeFormat 
1460408617738810.pdfPublished version441.85 kBAdobe PDFView/Open
Title: A one-year cost–utility analysis of REBOA versus RTACC for non-compressible torso haemorrhage
Authors: Renna, MS
Van Zeller, C
Abu-Hijleh, F
Tong, C
Gambini, J
Ma, M
Item Type: Journal Article
Abstract: Introduction: Major trauma is a leading cause of death and disability in young adults, especially from massive noncompressible torso haemorrhage. The standard technique to control distal haemorrhage and maximise central perfusion is resuscitative thoracotomy with aortic cross-clamping (RTACC). More recently, the minimally invasive technique of resuscitative endovascular balloon occlusion of the aorta (REBOA) has been developed to similarly limit distal haemorrhage without the morbidity of thoracotomy; cost–utility studies on this intervention, however, are still lacking. The aim of this study was to perform a one-year cost–utility analysis of REBOA as an intervention for patients with major traumatic non-compressible abdominal haemorrhage, compared to RTACC within the U.K.’s National Health Service. Methods: A retrospective analysis of the outcomes following REBOA and RTACC was conducted based on the published literature of survival and complication rates after intervention. Utility was obtained from studies that used the EQ5D index and from self-conducted surveys. Costs were calculated using 2016/2017 National Health Service tariff data and supplemented from further literature. A cost–utility analysis was then conducted. Results: A total of 12 studies for REBOA and 20 studies for RTACC were included. The mean injury severity scores for RTACC and REBOA were 34 and 39, and mean probability of death was 9.7 and 54%, respectively. The incremental costeffectiveness ratio of REBOA when compared to RTACC was £44,617.44 per quality-adjusted life year. The incremental cost-effectiveness ratio, by exceeding the National Institute for Health and Clinical Effectiveness’s willingness-to-pay threshold of £30,000/quality-adjusted life year, suggests that this intervention is not cost-effective in comparison to RTACC. However, REBOA yielded a 157% improvement in utility with a comparatively small cost increase of 31.5%. Conclusion: Although REBOA has not been found to be cost-effective when compared to RTACC, ultimately, clinical experience and expertise should be the main factor in driving the decision over which intervention to prioritise in the emergency context.
Issue Date: 24-Nov-2017
Date of Acceptance: 27-Oct-2017
URI: http://hdl.handle.net/10044/1/56045
DOI: https://dx.doi.org/10.1177/1460408617738810
ISSN: 1460-4086
Publisher: SAGE Publications
Journal / Book Title: Trauma
Copyright Statement: his article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords: 1103 Clinical Sciences
Publication Status: Published
Appears in Collections:Repository Tools

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons